PhoenixBio Co., Ltd. (TYO:6190)
243.00
-6.00 (-2.41%)
Nov 18, 2026, 11:11 AM JST
PhoenixBio Revenue
PhoenixBio had revenue of 300.00M JPY in the quarter ending September 30, 2026, a decrease of -15.73%. This brings the company's total for the last twelve months to 1.37B, down -9.41% year-over-year. In the fiscal year ending March 31, 2026, PhoenixBio had annual revenue of 1.57B with 1.56% growth. That makes PhoenixBio the 38,063rd largest company in the world by revenue and 3,752nd in Japan.
Revenue (ttm)
1.37B
Revenue Growth
-9.41%
P/S Ratio
0.74
Revenue / Employee
24.85M
Employees
55
Market Cap
989.06M
Revenue by Geography
- United States of America 853.06M 54.5%
- Japan 423.63M 27.1%
- Europe 193.88M 12.4%
- Others 94.97M 6.1%
Fiscal year ended Mar 31, 2026 See the full PhoenixBio breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 1.57B | 24.00M | 1.56% |
| Mar 31, 2025 | 1.54B | -174.00M | -10.15% |
| Mar 31, 2024 | 1.72B | -409.00M | -19.26% |
| Mar 31, 2023 | 2.12B | 800.00M | 60.42% |
| Mar 31, 2022 | 1.32B | 311.00M | 30.70% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 14.02B |
| Kohjin Bio | 4.38B |
| Human Metabolome Technologies | 1.48B |
| PRISM BioLab Co.,LTD | 518.00M |
| D. Western Therapeutics Institute | 140.90M |
| Veritas In Silico | 84.42M |
| Ribomic | 19.00M |
| FunPep Company | 2.00M |